EA201892524A1 - Днк-моноклональные антитела, нацеленные на il-6 и cd126 - Google Patents

Днк-моноклональные антитела, нацеленные на il-6 и cd126

Info

Publication number
EA201892524A1
EA201892524A1 EA201892524A EA201892524A EA201892524A1 EA 201892524 A1 EA201892524 A1 EA 201892524A1 EA 201892524 A EA201892524 A EA 201892524A EA 201892524 A EA201892524 A EA 201892524A EA 201892524 A1 EA201892524 A1 EA 201892524A1
Authority
EA
Eurasian Patent Office
Prior art keywords
monoclonal antibodies
antibodies targeted
dna monoclonal
composition
dna
Prior art date
Application number
EA201892524A
Other languages
English (en)
Russian (ru)
Inventor
Дэвид Уэйнер
Сара Эллиотт
Original Assignee
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания
Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания, Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи filed Critical Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания
Publication of EA201892524A1 publication Critical patent/EA201892524A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/248IL-6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EA201892524A 2016-05-05 2017-05-05 Днк-моноклональные антитела, нацеленные на il-6 и cd126 EA201892524A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662332377P 2016-05-05 2016-05-05
PCT/US2017/031193 WO2017192933A1 (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting il-6 and cd126

Publications (1)

Publication Number Publication Date
EA201892524A1 true EA201892524A1 (ru) 2019-04-30

Family

ID=60203626

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892524A EA201892524A1 (ru) 2016-05-05 2017-05-05 Днк-моноклональные антитела, нацеленные на il-6 и cd126

Country Status (12)

Country Link
US (1) US20190192692A1 (https=)
EP (1) EP3452106A4 (https=)
JP (3) JP7311113B2 (https=)
KR (3) KR20190031439A (https=)
CN (1) CN109789224A (https=)
AU (2) AU2017261292B2 (https=)
BR (1) BR112018072697A2 (https=)
CA (1) CA3023089A1 (https=)
EA (1) EA201892524A1 (https=)
MX (2) MX2018013523A (https=)
SG (2) SG10202011023YA (https=)
WO (1) WO2017192933A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110167584B (zh) * 2016-11-07 2024-06-07 威斯塔解剖学和生物学研究所 用于针对莱姆病的dna抗体构建体
KR102635888B1 (ko) 2019-03-19 2024-02-15 엘지전자 주식회사 공기청정기
JP2024504614A (ja) * 2021-01-14 2024-02-01 トランスレイト バイオ, インコーポレイテッド mRNAがコードする抗体を送達する方法および組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0214168B8 (pt) * 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
PE20061324A1 (es) * 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
EP2336181A1 (en) * 2005-12-09 2011-06-22 UCB Pharma, S.A. Antibody molecules having specificity for human IL-6
MX2009001110A (es) * 2006-08-03 2009-05-11 Vaccinex Inc Anticuerpos monoclonales anti-il-6 y usos de los mismos.
WO2009140348A2 (en) 2008-05-13 2009-11-19 Novimmune Sa Anti-il-6/il-6r antibodies and methods of use thereof
WO2011084714A2 (en) 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
US9304134B2 (en) 2010-11-23 2016-04-05 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of anemia
CA2889723A1 (en) * 2012-12-13 2014-06-19 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
WO2015054293A1 (en) * 2013-10-07 2015-04-16 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of psoriatic arthritis

Also Published As

Publication number Publication date
BR112018072697A2 (pt) 2019-02-19
JP2025147175A (ja) 2025-10-06
AU2017261292B2 (en) 2024-06-06
CA3023089A1 (en) 2017-11-09
SG11201809786TA (en) 2018-12-28
AU2024203109A1 (en) 2024-05-30
AU2017261292A1 (en) 2018-12-20
WO2017192933A1 (en) 2017-11-09
KR20230058733A (ko) 2023-05-03
MX2018013523A (es) 2019-06-10
US20190192692A1 (en) 2019-06-27
EP3452106A1 (en) 2019-03-13
MX2025009846A (es) 2025-09-02
KR20190031439A (ko) 2019-03-26
EP3452106A4 (en) 2020-01-08
SG10202011023YA (en) 2020-12-30
JP2019518074A (ja) 2019-06-27
JP7311113B2 (ja) 2023-07-19
CN109789224A (zh) 2019-05-21
JP2023086734A (ja) 2023-06-22
KR20250011241A (ko) 2025-01-21

Similar Documents

Publication Publication Date Title
EA201892522A1 (ru) Днк-моноклональные антитела, нацеленные на молекулы контрольных точек
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
EA201890874A1 (ru) Антитела, которые эффективно нейтрализуют вирус гепатита в, и их применение
PH12016501212A1 (en) Human anti-il-33 neutralizing monoclonal antibody
EA201892793A1 (ru) Анти-hla-g специфические антитела
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201791093A1 (ru) Антитела к cd47, способы и применение
EA201992091A1 (ru) Анти-c5 антитела и их применение
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
PE20150023A1 (es) Proteinas de union a antigeno st2
UA123202C2 (uk) Антитіло до тау-білка і його застосування
EA201592285A1 (ru) Антигенсвязывающие белки к рецептору онкостатина м
EA201892063A1 (ru) МОДИФИЦИРОВАННЫЕ ИММУНОГЛОБУЛИНЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ FcRn
EA202090559A1 (ru) Мультиспецифические антитела, специфичные в отношении эпитопов вируса зика, и их применение
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
EA201992206A1 (ru) Моноклональное антитело к pd-l1
MY184189A (en) Methods of treating nail and scalp psoriasis
MX2024006289A (es) Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
EA201892525A1 (ru) Конструкции днк-антител для применения против pseudomonas aeruginosa
EA201892524A1 (ru) Днк-моноклональные антитела, нацеленные на il-6 и cd126
EA202090864A1 (ru) Моноклональное антитело к il-5r
EA201990768A1 (ru) Оптимизированные синтетические консенсусные иммуногенные композиции, нацеленные на белок активации фибробластов
EA201892124A1 (ru) Днк-конструкции антител и способы их применения